Xeris Biopharma Holdings, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 2B30.F | AMLX | SUPN | 42C.SI | NBIX | AQST | |
|---|---|---|---|---|---|---|
| Market cap | 1.66B | 3.69B | 1.64B | 515.12M | 16.81B | 476.94M |
| P/E (TTM) | — | — | — | — | 24.6 | — |
| Forward P/E | — | -27.0 | 6.3 | 247.4 | 13.9 | -6.7 |
| Price/book | -182.9 | 13.7 | -55.5 | 33.6 | 4.3 | -6.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +6.91% | +135.96% | −11.32% | +259.26% | +7.27% | −38.01% |
| Today | +0.75% | +0.68% | +0.21% | −3.09% | +0.73% | −2.06% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All 2B30.F news ›Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $255,750.00 in Stock
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Beth Hecht sold 25,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value…
Xeris Biopharma Holdings, Inc. $XERS Stake Raised by Profund Advisors LLC
Posted by Danessa Lincoln on Nov 2nd, 2026 Read Our Latest Stock Report on Xeris Biopharma Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma…
Xeris Biopharma (NASDAQ:XERS) Stock Jumps 6.8% – Here’s What Happened
Posted by Sarita Garza on Oct 19th, 2026 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report)’s share price rose 6.8% during mid-day trading on Monday. The company traded as high as $11.05 and last traded at $11.0160.…
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
RECORLEV (levoketoconazole) is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Limitations of…
Xeris Biopharma Holdings, Inc. Reports Material Event
Healthcare Triangle, Inc. Announces 1-for-20 Reverse Stock Split as Part of Nasdaq Compliance Plan Greenland Energy Company Announces the Resignation of Roderick McIllree From the Board of Directors BlackRock Capital Allocation Term Trust…
Xeris Biopharma Files Patent Infringement Lawsuits In US District Court - SEC Filing
TradingView Xeris Biopharma Files Patent Infringement Lawsuits In US District Court - SEC Filing
Head-To-Head Survey: Organon & Co. (NYSE:OGN) versus Xeris Biopharma (NASDAQ:XERS)
Posted by Michael Walen on Oct 19th, 2026 Xeris Biopharma (NASDAQ:XERS – Get Free Report) and Organon & Co. (NYSE:OGN – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com5
- defenseworld.net1
- stocktitan.net1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.